Skip to main content
. 2021 Sep 2;7(9):e07916. doi: 10.1016/j.heliyon.2021.e07916

Table 1.

Characteristics of patient groups (N = 29) with HLA-Heterozygous and HLA-Homozygous.

HLA-Heterozygous (N = 25) HLA-Homozygous (N = 4) P
General characteristic
Age, years 69.7 ± 11.2 76.5 ± 6.2 0.25
Male, No. (%) 14 (56.0%) 2 (50.0%) 1.00
BMI, kg/m2 24.5 ± 5.2 23.1 ± 1.5 0.60
Performance status 0.50
  • -

    0, No. (%)

 5 (20.0%) 2 (50.0%)
  • -

    1–4, No. (%)

 20 (80.0%) 2 (50.0%)
Smoking, pack-year (%) 46.6 ± 40.0 31.2 ± 46.1 0.49
COPD, No. (%) 4 (16.0%) 1 (25.0%) 1.00
Lung cancer type 0.56
  • -

    Non-squamous cell carcinoma, No. (%)

 18 (72.0%) 4 (100.0%)
  • -

    Squamous cell carcinoma, No. (%)

 7 (28.0%) 0 (0.0%)
Lung cancer stage 1.00
  • -

    Stage 1–3, No. (%)

 6 (24.0%) 1 (25.0%)
  • -

    Stage 4, No. (%)

 19 (76.0%) 3 (75.0%)
Best overall response 0.37
  • -

    Non-applicable, No. (%)

  • -

    Non-CR/Non-PD, No. (%)

 5 (20.0%)
2 (8.0%)		 0 (0.0%)
0 (0.0%)
  • -

    PD, No. (%)

 3 (12.0%) 2 (50.0%)
  • -

    PR, No. (%)

 5 (20.0%) 1 (25.0%)
  • -

    SD, No. (%)

 10 (40.0%) 1 (25.0%)
Laboratory findings
Blood WBC count, x 109/L 9.1 ± 3.6 7.4 ± 2.7 0.39
Blood Hemoglobin, g/dL 11.8 ± 2.1 12.9 ± 0.8 0.32
Blood Platelet count, x 109/L 345.3 ± 136.9 311.5 ± 39.0 0.63
Blood Neutrophil count, % 73.5 ± 13.0 70.1 ± 13.6 0.64
Blood Lymphocyte count, % 15.6 ± 10.2 18.5 ± 9.4 0.60
Oncology testing panel findings
PD-L1 (IHC) 0.55
  • -

    <1%, No. (%)

 7 (28.0%) 2 (50.0%)
  • -

    1%<= <50%, No. (%)

 14 (56.0%) 2 (50.0%)
  • -

    50%≤, No. (%)

 4 (16.0%) 0 (0.0%)
Tumor Mutation Burden, m/MB 6.2 ± 4.4 2.3 ± 1.8 0.10
Neoantigen, No. (%) 6.5 ± 7.4 1.8 ± 1.3 0.01
Frameshift mutations 0.20
  • -

    0, No. (%)

 9 (36.0%) 1 (25.0%)
  • -

    1, No. (%)

 6 (24.0%) 3 (75.0%)
  • -

    2, No. (%)

 7 (28.0%) 0 (0.0%)
  • -

    3, No. (%)

 3 (12.0%) 0 (0.0%)

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; PD, progressive of disease; PR, partial response; SD, stable disease; WBC, white blood cell; PD-L1, programmed death-ligand1; IHC, immunohistochemistry.